New HER2 Drug for Breast Cancer Stalled by FDA

The FDA said it needs more data the new antibody-drug conjugate (ADC) trastuzumab duocarmazine for use in advanced or metastatic breast cancer.

Related Keywords

United Kingdom ,United States ,Marco Timmers ,Drug Administration ,European Union ,Metastatic Breast Carcinoma ,Antineoplastic Drug ,Nti Cancer Agents ,Evacizumab ,Rlotinib ,Efitinib ,Matinib ,Ituximab ,U11248 ,Unitinib ,Rastuzumab ,Biologic Therapy ,Humanized Monoclonal Antibody ,Breast Cancer ,Alignant Breast Neoplasm ,Her2 Positive Breast Cancer ,Her2 Breast Cancer ,Breast ,Cancer ,Alignant Neoplasia ,Arcinoma ,Antibody Drug Conjugates Adcs ,To ,